0001570562-24-000095.txt : 20240606
0001570562-24-000095.hdr.sgml : 20240606
20240606190124
ACCESSION NUMBER: 0001570562-24-000095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240604
FILED AS OF DATE: 20240606
DATE AS OF CHANGE: 20240606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOATAZEDI DAVID
CENTRAL INDEX KEY: 0001700836
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38381
FILM NUMBER: 241026813
MAIL ADDRESS:
STREET 1: C/O OBALON THERAPEUTICS, INC.
STREET 2: 5421 AVENIDA ENCINAS, SUITE F
CITY: CARLSBAD
STATE: CA
ZIP: 92008
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evolus, Inc.
CENTRAL INDEX KEY: 0001570562
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461385614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
BUSINESS PHONE: (949) 284-4555
MAIL ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
4
1
wk-form4_1717714876.xml
FORM 4
X0508
4
2024-06-04
0
0001570562
Evolus, Inc.
EOLS
0001700836
MOATAZEDI DAVID
520 NEWPORT CENTER DR.
SUITE 1200
NEWPORT BEACH
CA
92660
1
1
0
0
See Remarks
0
Common Stock
2024-06-04
4
S
0
140214
12.7283
D
533349
D
Common Stock
2024-06-05
4
M
0
155278
5.46
A
688627
D
Common Stock
2024-06-05
4
S
0
155278
12.9217
D
533349
D
Common Stock
2024-06-06
4
M
0
175940
7.28
A
709289
D
Common Stock
2024-06-06
4
S
0
175940
12.5866
D
533349
D
Stock Option (Right to Buy)
5.46
2024-06-05
4
M
0
155278
0
D
2032-01-25
Common Stock
155278
155281
D
Stock Option (Right to Buy)
7.28
2024-06-06
4
M
0
175940
0
D
2028-05-06
Common Stock
175940
1006079
D
The shares were sold in multiple trades at prices ranging from $12.70 to $12.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The shares were sold in multiple trades at prices ranging from $12.77 to $13.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The shares were sold in multiple trades at prices ranging from $12.40 to $12.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The shares subject to the option vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
The shares subject to the option vested in full over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 6, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
CEO and President
/s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi
2024-06-06